Haemonetics Co. (NYSE:HAE) Shares Sold by Marshall Wace LLP

Marshall Wace LLP lessened its holdings in shares of Haemonetics Co. (NYSE:HAE) by 44.8% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 44,892 shares of the medical instruments supplier’s stock after selling 36,503 shares during the quarter. Marshall Wace LLP’s holdings in Haemonetics were worth $3,714,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of HAE. Goldman Sachs Group Inc. increased its position in shares of Haemonetics by 14.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 191,253 shares of the medical instruments supplier’s stock worth $16,354,000 after acquiring an additional 24,394 shares in the last quarter. Quantbot Technologies LP raised its position in Haemonetics by 2,101.6% in the first quarter. Quantbot Technologies LP now owns 14,068 shares of the medical instruments supplier’s stock valued at $1,201,000 after purchasing an additional 13,429 shares during the period. Silvercrest Asset Management Group LLC purchased a new position in Haemonetics in the first quarter valued at about $38,706,000. Allspring Global Investments Holdings LLC boosted its position in shares of Haemonetics by 132.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 502,993 shares of the medical instruments supplier’s stock worth $42,930,000 after buying an additional 286,897 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Haemonetics by 38.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 562,454 shares of the medical instruments supplier’s stock worth $48,006,000 after buying an additional 156,665 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

HAE has been the topic of several recent research reports. Bank of America started coverage on Haemonetics in a research report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price target on the stock. Citigroup reduced their target price on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. CL King started coverage on shares of Haemonetics in a report on Friday, September 13th. They set a “buy” rating and a $116.00 price target for the company. Needham & Company LLC raised shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price target on the stock in a research note on Wednesday, June 12th. Finally, Barrington Research reissued an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a research report on Monday, September 23rd. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Haemonetics currently has an average rating of “Moderate Buy” and a consensus target price of $106.14.

Insider Activity

In related news, EVP Anila Lingamneni sold 2,136 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total transaction of $192,240.00. Following the transaction, the executive vice president now directly owns 21,410 shares in the company, valued at $1,926,900. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Haemonetics news, EVP Anila Lingamneni sold 2,136 shares of the stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $90.00, for a total transaction of $192,240.00. Following the sale, the executive vice president now directly owns 21,410 shares of the company’s stock, valued at $1,926,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Stewart W. Strong sold 4,312 shares of Haemonetics stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $91.15, for a total transaction of $393,038.80. Following the completion of the transaction, the insider now directly owns 18,196 shares of the company’s stock, valued at $1,658,565.40. The disclosure for this sale can be found here. Company insiders own 1.80% of the company’s stock.

Haemonetics Price Performance

Shares of HAE stock opened at $79.31 on Thursday. The firm has a fifty day moving average of $78.24 and a two-hundred day moving average of $84.04. The firm has a market cap of $4.04 billion, a P/E ratio of 34.63, a P/E/G ratio of 1.19 and a beta of 0.30. Haemonetics Co. has a 1-year low of $70.74 and a 1-year high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The firm had revenue of $336.17 million during the quarter, compared to analyst estimates of $335.08 million. During the same quarter last year, the business posted $1.05 earnings per share. The firm’s revenue for the quarter was up 8.0% on a year-over-year basis. As a group, research analysts anticipate that Haemonetics Co. will post 4.57 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.